Putrescine

Drug Profile

Putrescine

Alternative Names: Fibrostat; Putrescine dihydrochloride

Latest Information Update: 06 Jul 2007

Price : $50

At a glance

  • Originator Ambrilia Biopharma
  • Developer Ambrilia Biopharma; Biovail Corporation
  • Class Biogenic amines; Diamines; Skin disorder therapies; Small molecules
  • Mechanism of Action Transglutaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Hypertrophic scars

Most Recent Events

  • 03 Mar 2006 Cellpep has merged with Procyon Biopharma to form Ambrilia Biopharma
  • 20 Jan 2005 Data from a media release have been added to the adverse events and Skin disorders therapeutic trials sections
  • 21 Jul 2004 Procyon Biopharma has completed enrolment in a phase IIb trial for Hypertrophic scars in the US and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top